Late kidney dysfunction in a kidney transplant recipient

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 590-597

  Josephson, Michelle A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOSPORIN; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD PRESSURE; CASE REPORT; FIBROSIS; FLOW CYTOMETRY; HEART RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; PLASMAPHERESIS; RENAL GRAFT DYSFUNCTION; SPLENECTOMY;

ACUTE DISEASE; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT C4B; CREATININE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMA EXCHANGE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896873720     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07390713     Document Type: Article

References (54)

1. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, Held E, Riethmüller G, Land W, Albert E: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 86: 464-470, 1991
2. Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmüller G, Land W, Albert E: Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 43: 1333-1338, 1993
3. Cornell LD: Renal allograft pathology in the sensitized patient. Curr Opin Organ Transplant 18: 327-336, 2013
4. Racusen LC, Haas M: Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 1: 415- 420, 2006
5. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714, 2003
6. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8: 753-760, 2008
7. Haas M: C4d-negative antibody-mediated rejection in renal allografts: Evidence for its existence and effect on graft survival. Clin Nephrol 75: 271-278, 2011
8. Sis B, Campbell PM, Mueller T, Hunter C, Cockfield SM, Cruz J, Meng C, Wishart D, Solez K, Halloran PF: Transplant glomerulopathy, late antibody-mediated rejection and the ABCDtetrad in kidney allograft biopsies for cause. Am J Transplant 7: 1743-1752, 2007
9. Baid-Agrawal S, Farris AB 3rd, Pascual M, Mauiyyedi S, Farrell ML, Tolkoff-Rubin N, Collins AB, Frei U, Colvin RB: Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 80: 879-885, 2011
10. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95: 410-417, 2013
11. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF: De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 9: 2532-2541, 2009
12. Loupy A, Hill GS, Jordan SC: The impact of donor-specific anti- HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 8: 348-357, 2012
13. Lodhi SA, Lamb KE, Meier-Kriesche HU: Solid organ allograft survival improvement in the United States: The long-term does not mirror the dramatic short-term success. Am J Transplant 11: 1226-1235, 2011
14. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG: Identifying specific causes of kidney allograft loss. Am J Transplant 9: 527-535, 2009
15. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ: Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007
16. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508, 2009
17. Snanoudj R, Royal V, Elie C, Rabant M, Girardin C, Morelon E, Kreis H, Fournet JC, Noël LH, Legendre C: Specificity of histological markers of long-term CNI nephrotoxicity in kidneytransplant recipients under low-dose cyclosporine therapy. Am J Transplant 11: 2635-2646, 2011
18. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699-705, 1984
19. Morris PJ, Chapman JR, Allen RD, Ting A, Thompson JF, Dunnill MS, Wood RF: Cyclosporin conversion versus conventional immunosuppression: Long-term follow-up and histological evaluation. Lancet 1: 586-591, 1987
20. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
21. Mourer JS, Hartigh J, Van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW: Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 93: 887-894, 2012
22. A sberg A, Apeland T, Reisaeter AV, Foss A, Leivestad T, Heldal K, Thorud LO, Eriksen BO, Hartmann A; NILS Study Group: Longterm outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial. Clin Transplant 27: E151-E156, 2013
23. Opelz G, Döhler B: Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 86: 371-376, 2008
24. Gourishankar S, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, Gaston R, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J, Mannon R, Matas A: Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 10: 324-330, 2010
25. Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, Cecka JM, Gaston RS, Cosio F, Gourishankar S, Halloran PF, Hunsicker L, Rush D; DeKAF Investigators: Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 10: 2066-2073, 2010
26. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ: Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90: 68-74, 2010
27. Chapman JR: Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 11: 693-697, 2011
28. Matas AJ: Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 11: 687-692, 2011
29. Mengel M, Mihatsch M, Halloran PF: Histological characteristics of calcineurin inhibitor toxicity-there is no such thing as specificity! Am J Transplant 11: 2549-2550, 2011
30. Arias M, Serón D, Moreso F, Bestard O, Praga M: Chronic renal allograft damage: Existing challenges. Transplantation 91 [Suppl]: S4-S25, 2011
31. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB: Chronic humoral rejection: identification of antibodymediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12: 574-582, 2001
32. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence.AmJ Transplant 12: 388-399, 2012
33. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9: 2520-2531, 2009
34. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 9: 2312-2323, 2009
35. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW: Evolution and clinical pathologic correlations of de novo donorspecific HLA antibody post kidney transplant. Am J Transplant 12: 1157-1167, 2012
36. El TM, Grande JP, Keddis MT, Rodrigo E, Chopra B, Dean PG, Stegall MD, Cosio FG: Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 13: 2334-2341
37. Nickerson PW, Rush DN: Rejection: An integrated response. Am J Transplant 13: 2239-2240, 2013
38. Jordan SC, Pescovitz MD: Presensitization: The problem and its management. Clin J Am Soc Nephrol 1: 421-432, 2006
39. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J AmSoc Nephrol 15: 3256-3262, 2004
40. Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD: In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 13: 55-62, 2004
41. Siskind E, Bhaskaran M, Boctor F, Shah K, Molmenti E: Treatment of late class II antibody-mediated rejection status postkidney transplantation: Two case reports. Int J Angiol 21: 107-110, 2012
42. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle- Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR: Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75: 1490-1495, 2003
43. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M: Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 9: 408-415, 2005
44. Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O: Plasmapheresis and intravenous immunoglobulin in early antibodymediated rejection of the renal allograft: A single-center experience. Ther Apher Dial 13: 108-112, 2009
45. Becker YT, Becker BN, Pirsch JD, Sollinger HW: Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996-1001, 2004
46. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C: Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9: 1099-1107, 2009
47. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, Segev DL, Montgomery RA: The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7: 842-846, 2007
48. Roberts DM, Jiang SH, Chadban SJ: The treatment of acute antibody-mediated rejection in kidney transplant recipients- a systematic review. Transplantation 94: 775-783, 2012
49. González-Roncero F, Suner M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M: Eculizumab treatment of acute antibody- mediated rejection in renal transplantation: Case reports. Transplant Proc 44: 2690-2694, 2012
50. Kocak B, Arpali E, Demiralp E, Yelken B, Karatas C, Gorcin S, Gorgulu N, Uzunalan M, Turkmen A, Kalayoglu M: Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: Case reports. Transplant Proc 45: 1022-1025, 2013
51. Tzvetanov I, Spaggiari M, Joseph J, Jeon H, Thielke J, Oberholzer J, Benedetti E: The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: Report of three cases and review of literature. Transplant Proc 44: 2971-2975, 2012
52. Bentall A, Cornell LD, Gloor JM, Park WD, Gandhi MJ, Winters JL, Chedid MF, Dean PG, Stegall MD: Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 13: 76-85, 2013
53. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC: Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 91: 1103-1109, 2011
54. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES: Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 9: 1063-1071, 2009